Bisnorcymserine

Drug Profile

Bisnorcymserine

Alternative Names: Bisnorcymcerine; BNC

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute on Aging; National Institutes of Health (USA)
  • Developer Cenomed BioSciences; National Institute on Aging; National Institutes of Health (USA); QR Pharma
  • Class Antidementias; Phenylcarbamates; Small molecules
  • Mechanism of Action Amyloid beta-protein precursor inhibitors; Butyrylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Cognition disorders
  • Discontinued Poisoning

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in USA (PO, Capsule)
  • 28 May 2018 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in USA (PO, Capsule)
  • 11 May 2016 Bisnorcymserine is still in phase I trials for Alzheimer's disease & Cognition disorders (In volunteers) in the US (NCT01747213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top